Cystinuria Clinical Trial
Official title:
A Multicentre, Randomized, Controlled Versus Placebo, Double-blinded, 4 Parallel Arms, Dose-ranging Main Study, to Evaluate the Efficacy, Safety and Tolerability and Acceptability of Repeated Doses of ADV7103, After 7 Days of Treatment, in Patients With Cystinuria, and an Efficacy and Safety Exploratory Study in the Youngest Children.
This is a multicenter, randomized, controlled versus placebo, double-blinded, 4 parallel arms, dose-ranging main study, to evaluate the efficacy, safety and tolerability, and acceptability of repeated doses of ADV7103, after 7 days of treatment, in patients with cystinuria, and an efficacy and safety exploratory study in the youngest children.
The study will target enrolling at least 15 subjects in each of the following age groups: 6 months - 5 years (B13CS part only); 6-11 years; 12-17 years and adults>18. Subjects will be in the study for up to 7 weeks. After screening and enrollment (up to 35 days), Eligible patients will be treated will alkalinizing treatment (SoC) at the well-adapted dose and regimen for 7 days. An in-patient visit is planned at the end of this period. The baseline evaluations, including urine pH and specific gravity, will be done during this inpatient visit, from Day -1 t0 to t24h. After this visit, patients are randomized in a balanced manner (1:1:1:1) to one of the 4 possible treatment arms, ADV7103 at a low dose, medium dose or high dose, or ADV7103 placebo. For patients in B13CS part, a period of titration is planned before the 7 days of treatment with ADV7103. No use of placebo in B13CS. Controls of urine pH will be done at the patient's home with a pocket glass electrode pH-meter on fresh urines, at least twice a day: before the administration of ADV7103, in the morning at t0 and in the evening at t12h (12hrs after last ADV7103 intake and before the next dose). Subjects will have the opportunity to subsequently enter a long-term, open-label extension. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02120105 -
Cystine Capacity Clinical Study (CysCap)
|
||
| Completed |
NCT02538016 -
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
|
N/A | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT00169806 -
Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis
|
N/A | |
| Completed |
NCT03663855 -
Effect of Increasing Doses of Tiopronin on Cystine Capacity in Patients With Cystinuria
|
Phase 2 | |
| Recruiting |
NCT02780297 -
Prospective Research Rare Kidney Stones (ProRKS)
|
||
| Recruiting |
NCT02026388 -
Rare Kidney Stone Consortium Biobank
|
||
| Recruiting |
NCT04818034 -
The Effect of Sodium-glucose Cotransporter (SGLT) 2 Inhibitors on Cystine Stone Formation: A Preliminary Study
|
Phase 2 | |
| Withdrawn |
NCT04137978 -
Study Evaluating Patients With Cystinuria
|
Phase 2/Phase 3 | |
| Recruiting |
NCT02942420 -
Bucillamine Phase 2 Trial in Patients With Cystinuria
|
Phase 2 | |
| Completed |
NCT05048563 -
Registry of Thiola EC Therapy
|
||
| Completed |
NCT02125721 -
Effect of Increasing Doses of Cystine Binding Thiol Drugs on Cystine Capacity in Patients With Cystinuria
|
Phase 4 | |
| Active, not recruiting |
NCT02910531 -
Lipoic Acid Supplement for Cystine Stone
|
Phase 2 | |
| Recruiting |
NCT00588562 -
Rare Kidney Stone Consortium Patient Registry
|
||
| Completed |
NCT02124395 -
Health-related Quality of Life in Rare Kidney Stone
|
||
| Not yet recruiting |
NCT05058859 -
Long Term Clinical Efficacy of Sodium-glucose Cotransporter-2 (SGLT-2) Inhibitor in Cystinurics
|
Phase 2 | |
| Active, not recruiting |
NCT03539926 -
This Study Evaluates the Superiority of Daily Self-pH Monitorization of Lit-control®pH Meter Compared to the Monitorization of Reactive Strips (Standard of Care).
|
N/A | |
| Completed |
NCT00381849 -
Use of an Herbal Preparation to Prevent and Dissolve Kidney Stones
|
Phase 1/Phase 2 | |
| Completed |
NCT03836144 -
Effect of Urine Alkalinazation on Urinary Inflammatory Markers in Patients With Cystinuria
|